Article

Effect of a novel food rich in miraculin on the intestinal microbiome of malnourished patients with cancer and dysgeusia

Julio Plaza-Diaz[1,2,3], Marco Brandimonte-Hernández[1], Bricia López-Plaza[4,5], Francisco Javier Ruiz-Ojeda[1,6,7,8], Ana Isabel Álvarez-Mercado[2,6,9], Lucía Arcos-Castellanos[4], Jaime Feliú-Batlle[10,11,12], Thomas Hummel[13], Samara Palma Milla[4,12,14,†], Angel Gil[1,2,6,7,†,*]

[1] Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain.
[2] Instituto de Investigación Biosanitaria IBS.GRANADA, Complejo Hospitalario Universitario de Granada, 18014 Granada, Spain.
[3] Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 8L1, Canada.
[4] Food, Nutrition and Health Platform, Hospital La Paz Institute for Health Research (IdiPAZ), 28046 Madrid, Spain.
[5] Medicine Department, Faculty of Medicine, Complutense University of Madrid, Plaza de Ramón y Cajal, s/n, 28040 Madrid, Spain.
[6] Institute of Nutrition and Food Technology "José Mataix", Centre of Biomedical Research, University of Granada, Avda. del Conocimiento s/n. Armilla, 18016 Granada, Spain.
[7] CIBEROBN (CIBER Physiopathology of Obesity and Nutrition), Instituto de Salud Carlos III, 28029 Madrid, Spain.
[8] RU Adipocytes and Metabolism, Helmholtz Diabetes Center at Helmholtz Munich, German Research Center for Environmental Health GmbH Neuherberg, 85764, Germany.
[9] Department of Pharmacology, University of Granada, 18071 Granada, Spain.
[10] Oncology Department, Hospital La Paz Institute for Health Research-IdiPAZ, Hospital Universitario La Paz, 28029 Madrid, Spain.
[11] CIBERONC (CIBER Cancer), Instituto de Salud Carlos III, 28029 Madrid, Spain.
[12] Medicine Department, Faculty of Medicine, Autonomous University of Madrid, Arzobispo Morcillo 4, 28029 Madrid, Spain.
[13] Smell & Taste Clinic, Department of Otorhinolaryngology, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany.
[14] Nutrition Department, Hospital University La Paz, 28046 Madrid, Spain.
[†] These authors contributed equally to this work
[*] Correspondence: agil@ugr.es (A.G.); Tel.: +34-695466922 (A.G.)

Abstract: Dysgeusia contributes to nutritional derangement and worsens the quality of life of patients with cancer. Despite the different strategies, there is no effective treatment for patients suffering from taste disorders provided by the pharmaceutical industry. We developed a novel strategy for reducing side effects in cancer patients by providing a novel food supplement with the taste-modifying glycoprotein miraculin, which is approved by the European Union, as an adjuvant to medical-nutritional therapy. A pilot randomized, parallel, triple-blind, and placebo-controlled intervention clinical trial was carried out in which 31 malnourished patients with cancer and dysgeusia receiving antineoplastic treatment, and were randomized into three arms: standard dose of DMB (150 mg DMB/tablet), high dose of DMB (300 mg DMB/tablet) or placebo (300 mg freeze-dried strawberry) for three months. Patients consumed a DMB or placebo tablet before each main meal (breakfast, lunch and dinner). Using stool samples from patients with cancer, we analyzed the intestinal microbiome via nanopore methodology. We detected differences in the relative abundances of genera *Phocaeicola* and *Escherichia* depending on the treatment. Nevertheless, only the *Solibaculum* genus was more abundant in the standard-dose DMB group after 3 months. At the species level, *Bacteroides* sp. PHL 2737 presented a relatively low abundance in both DMB groups, and *Vescimonas coprocola* presented a relatively high abundance in both treatment groups after 3 months. Furthermore, a standard dose of DMB was positively associated with TNF-α levels and *Lachnoclostridium* and *Mediterraneibacter* abundances, whereas a high dose of DMB was negatively associated with TNF-α levels and the relative abundance of *Phocaeicola*. After a high dose of DMB, erythrocyte polyunsaturated fatty acids were positively correlated with *Lachnoclostridium* and *Roseburia*, and there was a positive association between *Phocaeicola* and the acetic acid concentration of feces. The intake of DMB

together with nutritional treatment and individualized dietary advice results in positive changes in the intestinal microbiome of patients with cancer and dysgeusia There was a negative association between the relative abundance of *Phocaeicola* and taste perception in the DMB high dose group. Changes observed in the intestinal microbiota might contribute to maintaining an appropriate immune response of cancer patients. Since the present pilot study involved only a few participants, further research is needed to draw robust conclusions.

Keywords: cancer, neoplasms, dysgeusia, malnutrition, intestinal microbiota, dried miracle berries, taste disorders.

1. Introduction

Cancer is characterized by uncontrolled cell proliferation [1]. The disease affects people in many ways, including psychologically, physically, economically, and socially [2]. Many patients with cancer may benefit from systemic therapy, chemotherapy, and radiotherapy; however, these treatments are also associated with a high risk of serious complications [3].

Malnutrition is estimated to be responsible for the death of 10-20% of patients with cancer [4]. However, nutritional support is received by only 30%-60% of cancer patients who are at risk of malnutrition [4].

Despite possible adverse consequences, taste changes experienced by patients with cancer are not usually diagnosed and treated early because clinicians do not consider them life-threatening [5-7]. It is estimated that 45 to 80% of patients with chemotherapy-induced taste changes will experience these changes [8-10]. Dysgeusia is the umbrella term for qualitative and quantitative taste dysfunction, and includes taste distortions with bitter, metallic, salty, or unpleasant tastes [11-13]. The consequences of taste alterations are the deterioration of nutritional status, a reduction in quality of life, weight loss, and ultimately, health [14-17]. Zinc, amifostine, selenium, lactoferrin, and cannabinoids are currently used to treat taste disorders; however, their effectiveness is limited [18-20].

The gut microbiota plays a crucial role in maintaining health, influencing not only the gastrointestinal tract, but also distant organs such as the brain, liver, and pancreas [21,22]. The composition of the gut microbiota is diverse: it is composed of more than 200 bacterial species [23,24] (including phylotypes such as *Bacillota, Bacteroidota, Actinomyces, Fusobacterium, Pseudomonadota, and Verrucomicrobiota*) [25], fungi (*Candida albicans*), viruses and protists [26]. Microorganisms that belong to a separate kingdom of living organisms, *Archaebacteria*, are also an important part of the intestinal microbiota [27]. An alteration in the equilibrium of the gut microbiota can result in the development of a dysbiotic state, with subsequent implications for both local and systemic health outcomes [28]. Thus, dysbiosis contributes to a variety of pathologies, including obesity [29], diabetes [30], neurodegenerative diseases [31], and cancer [32]. Approximately 20% of all cancers are strongly associated with specific viral or microbial infections [33]. Furthermore, bacteria have been identified as key factors in the progression of several types of cancer, including oral squamous cell carcinomas, colorectal cancer, and pancreatic ductal adenocarcinoma [34-36].

The complexity of the gut microbiome, as well as its richness and abundance, predicts the metabolic health of the host [37]. Several factors contribute to the composition of the gut microbiome, including diet and dietary habits. Unsurprisingly, the gut microbiome has been associated with several cancer determinants, such as taste perception, which influences appetite regulation and energy metabolism [37]. Furthermore, there is evidence that the gut microbiota can affect the response to systemic cancer therapy [38].

Miraculin is a glycoprotein obtained from the *Synsepalum dulcificum* berries that converts a sour taste into a sweet taste, which is why the fruit is also called "miracle berry" [39]. The taste-modifying effect of miraculin occurs under acidic conditions and lasts for approximately 30 minutes after consumption. Two small non-randomized studies using

non-objective tools tried to evaluate the effect of miracle fruit on taste disorders in patients with cancer who are receiving active chemotherapy treatment describing promising results [15,40]. Dried miracle berries (DMB) was approved as a novel food by the European Commission in December 2021. In addition to its taste-modifying properties, DMB also contains bioactive ingredients, such as fiber and phenolic compounds [41,42].

In a pilot randomized, parallel, triple-blind, and placebo-controlled clinical trial (the CLINMIR study), our research group provided clinical evidence on the efficacy of DMB in improving taste alterations in cancer patients. As a result of this study, we observed improvements in electrochemical food perception, energy and nutrient intake, nutritional status, and quality of life for malnourished patients with cancer receiving antineoplastic treatment [43]. Moreover, we showed that regular consumption of DMB consumption and nutritional interventions changed the oral microbiome in patients with cancer and dysgeusia, which may contribute to maintaining an appropriate immune response without altering taste perception [44]. The purpose of the present study was to assess the intestinal microbiome of malnourished patients with cancer and dysgeusia after DMB consumption as a medical-nutritional adjuvant treatment.

2. Results

During the period of November 2022 to May 2023, 62 patients were assessed for eligibility. Among 31 patients with cancer who met the inclusion criteria, three intervention groups were randomly assigned according to the type of cancer. In the course of the study, ten participants withdrew from the study. Several of these dropouts were caused by taste distortions caused by acidic foods that were not sweet (n = 6) and the complexity of the intervention prescription (n = 2). During the course of the study, two placebo patients died. A total of 21 patients with cancer completed the clinical trial. All variables were analyzed with an intention-to-treat approach. The sample consisted of 58.1% women and 41.9% men, with an average age of 60.0 ± 10.9 years. Participants who were actively treated were assessed by electrogustometry; results of taste perception for the population have been published elsewhere [45].

2.1. Phylum level

At baseline, *Bacillota* and *Bacteroidota* accounted for more than 80% of the relative abundance of the intestinal microbiota. Based on the comparison between baseline and three months, no major differences were found among the groups. According to the treatment, only *Pseudomonadota* was significantly different among the three study groups. Both the alpha diversity indices (Shannon, Simpson and Chao1) and the studied phyla did not show any effect of treatment x time (Table 1).

2.2. Genus level

The most common genus in all the studied groups was *Faecalibacterium* (approximately 11 to almost 20 % relative abundance). There were differences between the genera *Phocaeicola* and *Escherichia* depending on the treatment. For *Solibaculum*, we observed significant differences in the interaction effect of treatment x time. The standard dose of DMB produced a significant increase in the relative abundance of *Solibaculum*, whereas the placebo resulted in a significant decrease in the relative abundance of this genus (Table 2).

2.3. Species level

Four species dominated the intestinal microbiota of cancer patients: *Faecalibacterium prausnitzii*, *Anaerobutyricum hallii*, and *Vescimonas coprocola* and *Vescimonas fastidiosa*. For *Bacteroides* sp. PHL 2737 and *Vescimonas coprocola*, we observed significant differences in the interaction between treatment and time; between baseline and 3 months, *Bacteroides* sp. PHL 2737 decreased significantly in both the DMB groups and *Vescimonas coprocola* decreased in the placebo group (Table 3).

Table 1. Relative abundances of intestinal bacteria at the phylum level in malnourished patients with cancer and dysgeusia who received standard-dose DMB (150 mg), high-dose DMB (300 mg) or placebo for 3 months.

Phylum	DMB 150 mg		DMB 300 mg		Placebo		p-value		
	Baseline	3 months	Baseline	3 months	Baseline	3 months	Treatment (T)	Time (t)	T x t
Actinobacteriota	0.3 (0.1 - 0.7)	0.4 (0.1 - 0.4)	0.2 (0.03 - 0.7)	0.2 (0.07 - 0.5)	0.3 (0.01 - 0.8)	0.1 (0.03 - 0.6)	0.717	0.357	0.468
Bacillota	78.1 (70.6 - 94.1)	88.6 (76 - 95.1)	75.7 (49.3 - 86)	74.7 (67.7 - 80.6)	69.1 (13.1 - 88.1)	73.7 (50.3 - 91.1)	0.062	0.224	0.598
Bacteroidota	14.6 (1.4 - 24.5)	8.2 (1.9 - 20.7)	8.9 (3.1 - 41.4)	16 (3 - 26.4)	10.2 (0.008 - 18.1)	6.7 (0.1 - 32.4)	0.444	0.674	0.888
Pseudomonadota	3.8 (2.2 - 7.9)	2 (1.2 - 12)	7.2 (4.6 - 24)	8.1 (3.4 - 21.5)	16.8 (2.7 - 86.8)	15.9 (4.2 - 31.4)	0.043*	0.253	0.366
Tenericutes	0.2 (0.01 - 0.3)	0.06 (0.01 - 0.2)	0.09 (0.01 - 0.2)	0.03 (0.008 - 0.2)	0.1 (0.006 - 0.4)	0.06 (0.01 - 0.2)	0.542	0.092	0.703
Synergistetes	0.1 (0.008 - 0.3)	0.08 (0.01 - 0.2)	0.08 (0.01 - 1.3)	0.2 (0.02 - 0.5)	0.2 (0.05 - 0.2)	0.1 (0.01 - 0.2)	0.282	0.397	0.876
Verrucomicrobiota	0.1 (0.006 - 0.9)	0.1 (0.01 - 1.5)	0.03 (0.007 - 1.3)	0.05 (0.01 - 0.2)	0.08 (0.07 - 1.2)	0.04 (0.01 - 2.4)	0.616	0.466	0.388
Shannon	3.3 (2.5 - 3.6)	3.3 (3.1 - 3.8)	3.3 (2.3 - 3.7)	3.3 (2.6 - 3.4)	3.3 (1.5 - 3.3)	3.0 (2.1 - 3.8)	0.150	0.879	0.745
Simpson	0.9 (0.8 - 0.9)	0.9 (0.9 - 1.0)	0.9 (0.8 - 0.9)	0.9 (0.9 - 0.9)	0.9 (0.5 - 0.9)	0.9 (0.8 - 1.0)	0.135	0.825	0.579
Chao1	435.2 (308.3 - 548.2)	388.7 (315.0 - 540.0)	404.7 (255.1 - 684.8)	422.6 (261.0 - 491.2)	394.7 (264.3 - 514.2)	415.6 (272.1 - 547.0)	0.367	0.139	0.202

The values are presented as medians and ranges. Based on the median test across time points within groups, *indicates significant differences ($p<0.05$).

Table 2. Relative abundances of intestinal bacteria at the genus level in malnourished patients with cancer and dysgeusia who received standard-dose DMB (150 mg), high-dose DMB (300 mg) or placebo for 3 months.

Genus	DMB 150 mg		DMB 300 mg		Placebo		p-value		
	First visit	3 months	First visit	3 months	First visit	3 months	Treatment (T)	Time (t)	T x t
Faecalibacterium	17.5 (5.7 - 34.1)	13.4 (12 - 24.2)	19.7 (4.6 - 28.8)	17.2 (4.6 - 28.8)	11.4 (0.01 - 35)	12.2 (0.05 - 46.3)	0.614	0.707	0.670
Prevotella	0.04 (0.01 – 10.8)	0.4 (0.01 – 15.8)	1.7 (0.02 – 30.9)	5.6 (0.1 – 23.8)	3.9 (0.01 – 15.5)	3.7 (0.1 – 27.9)	0.669	0.936	0.722
Blautia	4.2 (2.4 - 8.4)	4.9 (2.3 - 7.8)	4.7 (0.5 - 10.1)	3.9 (2.3 - 7.5)	2.9 (0.02 - 9)	2.9 (0.02 - 4.4)	0.382	0.236	0.828
Anaerobutyricum	4.0 (1 - 7.8)	2.4 (1.6 - 5.4)	2.6 (0.2 - 6.5)	2.3 (1.2 - 5.3)	1.9 (0.5 - 2.9)	3 (0.01 - 4.2)	0.369	0.848	0.126
Dysosmobacter	3.3 (0.8 - 4)	3.7 (0.7 - 6.3)	1.5 (0.5 - 7.1)	2.9 (0.3 - 9.3)	2.6 (1.3 - 3.8)	2.6 (0.02 - 6.2)	0.841	0.299	0.859
Vescimonas	3.3 (0.2 - 10.6)	3.3 (1.1 - 18.8)	2.6 (0.1 - 8.6)	1.3 (0.03 - 8.4)	6 (0.5 - 17.4)	2.8 (0.01 - 12.6)	0.450	0.977	0.130
Roseburia	2.8 (0.7 - 21.4)	1.7 (0.9 - 23.4)	2.4 (1.2 - 13.2)	3.6 (0.4 - 11.6)	1.6 (1.4 - 4.9)	3.2 (1.6 - 12.4)	0.830	0.506	0.547
Sulcia	2.8 (2.8 - 2.8)	1.1 (1.1 - 1.1)	0 (0 - 0)	0 (0 - 0)	0.3 (0.3 - 0.3)	0 (0 - 0)	1.0	1.0	1.0
Bacteroides	2.5 (0.4 - 9.4)	1.3 (0.7 - 4.8)	1.9 (0.8 - 14)	2.2 (0.6 - 8)	0.9 (0.3 - 15.5)	0.7 (0.02 - 7.7)	0.915	0.131	0.957
Lachnospira	2.1 (1.3 - 4)	2.5 (0.5 - 3.4)	2.5 (0.4 - 3.4)	1.3 (0.3 - 3.8)	1.1 (0.6 - 10.8)	1.8 (0.6 - 6.4)	0.576	0.459	0.874
Clostridium	1.8 (1.2 - 2.4)	1.9 (0.9 - 4.3)	2.1 (0.2 - 4.1)	1.3 (0.9 - 16.2)	1.2 (0.9 - 3.1)	1.4 (0.7 - 40.1)	0.614	0.182	0.513
Coprococcus	1.5 (1 - 3.6)	2.2 (0.8 - 2.8)	0.9 (0.06 - 5)	1.1 (0.2 - 2.2)	1 (0.2 - 2.7)	1.9 (0.5 - 2.9)	0.558	0.630	0.590
Blattabacterium	1.5 (1.5 - 1.5)	0.5 (0.5 - 0.5)	0 (0 - 0)	0 (0 - 0)	0.2 (0.2 - 0.2)	0 (0 - 0)	1.0	1.0	1.0
Phascolarctobacterium	1.4 (0.2 - 3)	1.9 (1.4 - 10.8)	2 (1.1 - 2.6)	1.6 (0.08 - 6.7)	0.03 (0.007 - 8.4)	0.01 (0.006 - 9.2)	0.966	0.206	0.586
Mediterraneibacter	1.3 (0.5 - 3.3)	0.8 (0.4 - 2.5)	1.6 (0.3 - 9)	1.5 (0.4 - 4.5)	0.7 (0.5 - 1.5)	0.8 (0.03 - 4.8)	0.379	0.514	0.350
Dorea	1.2 (0.9 - 2.9)	1.3 (0.8 - 2.8)	2.3 (0.3 - 4.3)	1 (0.07 - 10.2)	0.8 (0.06 - 1.9)	1 (0.09 - 1.4)	0.214	0.628	0.668
Phocaeicola	1.2 (0.3 - 5.2)	0.9 (0.09 - 2.8)	2.7 (0.3 - 4)	2.2 (0.6 - 4.2)	0.5 (0.3 - 0.7)	0.4 (0.4 - 0.5)	0.036*	0.430	0.619
Ruminococcus	1.1 (0.4 - 22.9)	0.9 (0.7 - 19.2)	0.8 (0.1 - 5.3)	0.8 (0.3 - 1)	1.7 (0.2 - 5.3)	1.2 (0.008 - 3.2)	0.491	0.055	0.841
Solibaculum	1.1 (0.4 - 10.8)	3.4* (0.8 - 7.8)	1 (0.07 - 6.7)	1 (0.08 - 6.4)	5.8 (0.03 - 8)	1.4* (0.02 - 3)	0.782	0.172	0.046*

Herbinix	1 (0.3 - 2.8)	1.6 (0.2 - 2.4)	0.6 (0.2 - 1.9)	0.8 (0.1 - 1.5)	1.1 (0.5 - 4.6)	1.5 (0.8 - 3.3)	0.403	0.740	0.685
Lachnoclostridium	0.9 (0.5 - 2.3)	0.6 (0.4 - 3)	0.8 (0.2 - 1.9)	0.6 (0.3 - 3.5)	0.6 (0.01 - 0.8)	0.6 (0.2 - 2.8)	0.487	0.103	0.934
Anaerostipes	0.9 (0.3 - 6.7)	1 (0.4 - 7.2)	0.8 (0.3 - 4)	0.8 (0.3 - 1.2)	0.5 (0.2 - 6)	1 (0.01 - 5.7)	0.801	0.617	0.806
Escherichia	0.8 (0.2 - 2.7)	0.3 (0.1 - 2.9)	1.3 (0.1 - 14)	1.7 (0.2 - 5)	1.1 (0.3 - 19.3)	3.4 (0.3 - 9.2)	0.012*	0.291	0.756

The values are presented as medians and ranges. Based on the median test across time points within groups, *indicates significant differences (p<0.05).

Table 3. Relative abundances of intestinal bacteria at the species level in malnourished patients with cancer and dysgeusia who received standard-dose DMB (150 mg), high-dose DMB (300 mg) or placebo for 3 months.

Species	DMB 150 mg		DMB 300 mg		Placebo		p-value		
	First visit	3 months	First visit	3 months	First visit	3 months	Treatment (T)	Time (t)	T x t
Bacteroides caccae	0.4 (0.04 - 0.9)	0.2 (0.01 - 1.0)	0.2 (0.07 - 1.1)	0.08 (0.04 - 0.3)	0.03 (0.02 - 0.4)	0.02 (0.02 - 1.0)	0.985	0.197	0.084
Bacteroides stercoris	0.2 (0.03 - 0.4)	0.2 (0.01 - 1.0)	0.2 (0.01 - 1.5)	0.5 (0.05 - 0.8)	0.1 (0.08 - 0.1)	0.3 (0.03 - 0.5)	0.587	0.608	0.713
Bacteroides thetaiotaomicron	0.5 (0.06 - 1.0)	0.3 (0.03 - 0.8)	0.07 (0.04 - 0.8)	0.1 (0.06 - 0.5)	0.1 (0.04 - 5.3)	0.2 (0.09 - 2.1)	0.591	0.197	0.475
Bacteroides uniformis	0.5 (0.03 - 2.7)	0.4 (0.08 - 2.1)	0.3 (0.03 - 1.9)	0.6 (0.03 - 2.1)	0.2 (0.06 - 0.4)	0.2 (0.1 - 0.5)	0.552	0.554	0.655
Bacteroides sp. PHL 2737	1.5 (0.8 - 2.2)	0.3* (0.3 - 0.3)	2.1 (0.2 - 4.0)	0.4* (0.2 - 2.2)	0.4 (0.3 - 0.4)	0.2 (0.2 - 0.2)	0.469	<0.001*	<0.001*
Anaerobutyricum hallii	4.0 (1.0 - 7.8)	2.5 (1.6 - 5.4)	2.6 (0.2 - 6.6)	2.3 (1.2 - 5.4)	1.9 (0.5 - 2.9)	3.0 (0.01 - 4.3)	0.366	0.853	0.128
Blautia argi	0.3 (0.2 - 0.9)	0.2 (0.2 - 0.5)	0.3 (0.04 - 0.9)	0.2 (0.1 - 0.4)	0.2 (0.1 - 0.3)	0.2 (0.1 - 0.3)	0.136	0.287	0.688
Blautia liquoris	1.0 (0.6 - 5.8)	1.0 (0.5 - 3.9)	1.0 (0.2 - 1.6)	1.2 (0.1 - 1.7)	0.4 (0.2 - 3.0)	0.9 (0.6 - 2.9)	0.624	0.606	0.364
Blautia massiliensis	0.6 (0.3 - 2.5)	0.9 (0.4 - 2.5)	1.4 (0.05 - 3.8)	1.0 (0.2 - 2.3)	0.5 (0.01 - 1.2)	0.4 (0.1 - 0.7)	0.194	0.265	0.426
Blautia obeum	0.4 (0.04 - 1.1)	0.07 (0.05 - 0.9)	0.1 (0.08 - 2.0)	0.04 (0.03 - 0.3)	0.1 (0.02 - 0.5)	0.1 (0.06 - 0.3)	0.620	0.269	0.521
Blautia pseudococcoides	0.1 (0.09 - 0.2)	0.2 (0.1 - 0.3)	0.2 (0.04 - 0.3)	0.1 (0.08 - 0.2)	0.1 (0.07 - 0.2)	0.09 (0.05 - 0.2)	0.199	0.945	0.801
Blautia sp. SC05B48	1.0 (0.4 - 1.9)	0.8 (0.4 - 2.9)	1.1 (0.1 - 3.8)	1.0 (0.5 - 4.4)	1.2 (0.5 - 8.3)	0.8 (0.3 - 2.9)	0.720	0.283	0.278
Lachnospira eligens	2.1 (1.3 - 4.0)	2.5 (0.6 - 3.4)	2.5 (0.4 - 3.4)	1.4 (0.3 - 3.8)	1.1 (0.6 - 10.8)	1.8 (0.6 - 6.5)	0.576	0.462	0.873
Roseburia hominis	2.5 (0.6 - 19.3)	1.7 (0.8 - 17.3)	2.0 (0.2 - 4.8)	2.3 (0.1 - 6.9)	1.4 (1.1 - 3.9)	2.7 (1.3 - 4.2)	0.561	0.975	0.356

	0.3	0.5	0.6	1.2	0.3	0.5			
Roseburia intestinalis	(0.07 - 2.0)	(0.1 - 5.5)	(0.03 - 8.8)	(0.2 - 4.5)	(0.1 -1.0)	(0.3 - 5.8)	0.533	0.421	0.494
	0.01	0.04	0.1	0.1	0.03	0.1			
Roseburia sp. NSJ-69	(0.007 - 0.3)	(0.02 - 0.8)	(0.01 - 0.3)	(0.01 - 0.5)	(0.02 - 0.09)	(0.08 - 2.4)	0.423	0.172	0.659
	17.7	13.9	19.8	17.3	11.5	12.3			
Faecalibacterium prausnitzii	(5.8 - 34.4)	(12.1 - 24.6)	(4.6 - 28.9)	(4.6 - 29.0)	(0.01 - 35.7)	(0.07 - 46.7)	0.620	0.712	0.678
	2.3	1.6	1.6	0.9	3.9	2.2*			
Vescimonas coprocola	(0.06 - 7.7)	(0.5 - 9.6)	(0.1 - 2.6)	(0.03 - 3.3)	(0.5 - 13.0)	(0.02 - 8.9)	0.245	0.889	0.049*
	1.1	2.5	1.0	0.7	2.2	1.3			
Vescimonas fastidiosa	(0.2 - 9.0)	(0.6 - 9.5)	(0.02 - 6.4)	(0.04 - 6.1)	(1.9 - 4.6)	(0.01 - 3.8)	0.719	0.881	0.563
	0.5	0.8	0.2	0.4	0.8	0.9			
Dysosmobacter sp. *Marseille*-Q4140	(0.3 - 1.0)	(0.2 - 2.2)	(0.03 - 1.5)	(0.03 - 1.3)	(0.5 - 0.9)	(0.4 - 1.1)	0.421	0.405	0.416
	2.5	3.1	1.3	2.3	1.8	1.9			
Dysosmobacter welbionis	(0.6 - 3.4)	(0.5 - 4.6)	(0.5 - 7.1)	(0.3 - 9.2)	(0.6 - 2.9)	(0.3 - 5.2)	0.897	0.207	0.988

The values are presented as medians and ranges. Based on the median test across time points within groups, *indicates significant differences ($p<0.05$).

2.4. Short-chain fatty acids

In all the study groups, acetic acid was the most abundant short-chain fatty acid. For acetic acid there were significant differences between times and the interaction of treatment and time. As a result of treatment with the standard dose of DMB, the acetic acid level increased significantly, whereas the level decreased in patients receiving the placebo treatment (Table 4).

Table 4. Plasma short-chain fatty acids in malnourished patients with cancer and dysgeusia who received standard-dose DMB (150 mg), high-dose DMB (300 mg) or placebo for 3 months.

Short-chain fatty acids	DMB 150 mg		DMB 300 mg		Placebo		p-value		
	Baseline	3 months	Baseline	3 months	Baseline	3 months	Treatment (T)	Time (t)	T x t
Acetic acid (μmol/L)	12.8 ± 6.4	26.7 ± 6.7*	36.6 ± 7.0	31.7 ± 7.3	25.0 ± 7.8	15.0 ± 8.2*	0.082	0.032*	0.027*
Propionic acid (μmol/L)	0.8 ± 0.6	2.2 ± 0.9	1.5 ± 0.6	0.6 ± 1.0	1.9 ± 0.7	2.6 ± 1.1	0.357	0.420	0.559
Isobutyric acid (μmol/L)	0.3 ± 0.1	0.4 ± 0.1	0.3 ± 0.1	0.3 ± 0.1	0.4 ± 0.1	0.4 ± 0.1	0.993	0.893	0.955
Butyric acid (μmol/L)	0.9 ± 0.3	1.3 ± 0.3	0.9 ± 0.3	0.8 ± 0.4	1.1 ± 0.3	1.3 ± 0.4	0.698	0.414	0.591
Isovaleric acid (μmol/L)	0.2 ± 0.1	0.3 ± 0.1	0.2 ± 0.1	0.3 ± 0.1	0.2 ± 0.1	0.4 ± 0.1	0.865	0.991	0.603
Valeric acid (μmol/L)	1.0 ± 0.8	2.2 ± 0.9	1.0 ± 1.5	0.7 ± 1.0	1.0 ± 1.9	2.7 ± 1.1	0.573	0.559	0.878

The values are presented as the means and standard deviations. Based on the median test across time points within groups, *indicates significant differences ($p<0.05$).

2.5. Rivera-Pinto for microbiota balance

To ascertain the microbiome balance at the conclusion of the trial, the Rivera-Pinto method was employed [46]. The analysis revealed that *Pseudomonadota*, was most associated with the placebo group when the standard-dose DMB group (150 mg) was compared with the placebo group (Figure 1A). In the standard-dose DMB group, lower balance scores were associated with lower relative abundances of *Roseburia, Phocaeicola, Escherichia* and *Streptococcus* than *Pseudomonadota* (Figure 1A). With respect to the high-dose DMB group versus the placebo group, *Escherichia* was the most strongly associated with the placebo group (Figure 1B). Thus, the higher the dose of DMB was, the lower the balance scores associated with lower relative abundances of *Actinobacteriota* than of *Escherichia* (Figure 1B).



Figure 1. Group balances are presented in an overview. The top of the plot indicates that groups of taxa constitute the global balance. Box plots illustrating the distribution of balance scores for the DMB 150 mg (standard dose) and placebo groups (A) and the DMB 300 mg (high dose) and placebo groups (B). On the right, the ROC curve with its AUC value and the density curve are displayed.

2.6. Analysis of the relationships among the intestinal microbiota, nutritional status, electrical taste perception inflammatory cytokines, , an plasma short-chain fatty acids.

In the group of patients with cancer and dysgeusia who received the standard dose of DMB, *Mediterraneibacter* had a negative correlation with saturated fatty acid percentage of energy in the diet. TNF-α levels were positively correlated with *Lachnoclostridium* and

Mediterraneibacter. The presence of the *Prevotella* genus was positively correlated with the electrogustometry values on the right side of the tongue and the proteolysis inducing factor (Figure 2A).

Several correlations were observed in the group that received high doses of DMB (Figure 2B). As a percentage of energy, *Blautia* and *Mediterraneibacter* were positively associated with lipids in the diet, whereas *Faecalibacterium* was negatively associated. *Mediterraneibacter* was positively correlated with dietary monounsaturated fatty acids. There was a positive correlation between dietary polyunsaturated fatty acids (PUFAs) and *Lachnoclostridium* and *Roseburia*. Dietary energy intake (%) was positively correlated with *Anaerobutyricum*. There was a negative correlation between the relative abundance of *Phocaeicola* and electrogustometry (both, right and left sides of the tongue), and TNF-α levels. Proteolysis inducing factor was positively correlated with the *Prevotella* genus. There was a positive correlation between *Phocaeicola* and plasma acetic acid concentration, whereas a negative correlation was detected between *Pseudomonadota* and TNF-α levels (Figure 2B).

A positive association between *Phocaeicola* and energy intake was detected in the placebo group. Dietary saturated fatty acids (%) were negatively associated with *Lachnospira*. Dietary monounsaturated fatty acids were positively correlated with *Anaerobutyricum* and *Blautia*. Dietary PUFAs were positively correlated with *Mediterraneibacter* and *Roseburia* (Figure 2C).







Figure 2. Correlations between the intestinal microbiota, nutritional status, electrical taste perception and inflammatory cytokines. A. DMB 150 mg (standard dose), B. DMB 300 mg (high dose), and C. placebo.

3. Discussion

The present study revealed that regular DMB consumption together with nutritional treatment and individualized dietary advice changed the composition of the gut microbiota. We found that the differences between the genera *Phocaeicola* and *Escherichia* were dependent on the treatment, but only the *Solibaculum* genus presented an increased relative abundance in the standard-dose DMB group following 3 months. After 3 months, *Bacteroides* sp. PHL 2737 showed greater relative abundance in both DMB groups, whereas *Vescimonas coprocola* was more abundant in both treatment groups. According to the electrogustometry results on the right side of the tongue of patients with cancer and dysgeusia receiving the standard dose of DMB, the presence of *Prevotella* genus was positively correlated with the electrogustometry values and proteolysis-inducing factor plasma levels. The TNF-α levels were positively correlated with *Lachnoclostridium* and *Mediterraneibacter*. The abundance of *Mediterraneibacter* was negatively correlated with dietary saturated fatty acids expressed as percentage of the dietary energy. In the group that received high doses of DMB, several correlations were observed. A negative correlation was found between the relative abundance of *Phocaeicola* and electrogustometry (both right and left sides of the tongue) as well as TNF-α levels. The proteolysis inducing factor was positively correlated with the *Prevotella* genus. *Anaerobutyricum* was positively correlated with the energy intake. *Blautia* and *Mediterraneibacter* were positively associated with lipids in the diet, whereas *Faecalibacterium* was negatively associated. The correlation between *Mediterraneibacter* and monounsaturated fatty acids was positive. *Lachnoclostridium* and *Roseburia* were positively correlated with dietary PUFAs. Also, our results revealed that *Phocaeicola* was positively correlated with the plasma acetic acid concentration, whereas *Pseudomonadota* was negatively correlated with the TNF-α levels.

According to Hes et al. (2024), the gut microbiome of patients with severe mucositis differ from that of patients with grades 1-2 mucositis, with an increase in the abundances of *Mediterraneibacter (Ruminococcus gnavus*) and *Clostridiaceae*, including *Hungatella hathewayi* [47]. As shown here, the habitual consumption of a standard dose of DMB was positively associated with TNF-α levels and *Lachnoclostridium,* and *Mediterraneibacter* abundances, whereas a high dose of DMB was negatively associated with TNF-α levels and the relative abundance of *Phocaeicola*. Microbes, as well as gut bacteria-derived metabolites, pathogen-associated molecular patterns, and antigens, can move from the gastrointestinal tract to other closely related tissues and impact cancer progression [48].

The *Bacteroides* and *Phocaeicola* species play crucial roles in the human colon. By degrading complex heteropolysaccharides into short-chain fatty acids, those organisms contribute to the body's use of these compounds [49]. Our findings indicate that the consumption of DMB at high doses is positively correlated with the abundance of the genus *Phocaeicola* and acetic acid concentrations. In addition, following DMB administration at a high dose, a positive correlation was found between PUFAs, *Lachnoclostridium*, and *Roseburia*. PUFAs have antitumor activity. In particular, it has been proposed that PUFAs, specifically eicosapentaenoic acid and docosahexaenoic acid, possess anticolorectal cancer activity [50]. A recent study investigated the impact of PUFA supplementation on the fecal microbiome in middle-aged, healthy volunteers, showing that PUFA supplementation leads to a reversible increase in bacteria that produce short-chain fatty acids [51]. Moreover, a reversible increase in the abundance of several bacterial genera, including *Bifidobacterium*, *Roseburia* and *Lactobacillus*, was observed in patients who received one or both PUFA treatments. Consequently, a high dose of DMB may enhance the presence of microorganisms that increase SCFA availability and contribute to PUFA consumption.

Numerous diseases in humans have been associated with changes in the gut microbiota composition, with fluctuations in the prevalence of particular bacterial groups. In this regard, *Faecalibacterium* is one of the most notable genera. The relative abundance of this bacteria was estimated to be between 11 and 20%. A recent study revealed a negative correlation between the abundance of *Faecalibacterium* and increased intraindividual variability in microbiota composition, indicating that it as a keystone taxon [52,53].

Certain species of *Faecalibacterium* have been observed to undergo alterations in a number of diseases and disorders. In fact, multiple studies have demonstrated that a high baseline level of *Faecalibacterium*, along with that of other *Bacillota*, is positively correlated with responses to related treatments for various cancers, including melanoma [54-58], hepatocellular carcinoma [59] and non-small cell lung cancer [60]. We observed a tendency to decrease concentration of *Faecalibacterium prausnitzii* in DMB groups.

We showed that standard dose of DMB administration resulted in a significant increase in the relative abundance of *Solibaculum* genus, whereas placebo resulted in a reduction of this genus. We identified four species of microbes that are dominant within the gastrointestinal tract of patients with cancer: *Faecalibacterium prausnitzii*, *Anaerobutyricum hallii*, *Vescimonas* species, *V. coprocola* and *V. fastidiosa*. However, we identified significant differences in the interaction effect between treatment and time for *Bacteroides* sp. PHL 2737 and *Vescimonas coprocola*. A significant decrease in *Bacteroides* sp. PHL 2737 levels was observed between the baseline and the three-month period in both the DMB groups. Additionally, *Vescimonas coprocola* levels decreased significantly in the placebo group. Environmental alterations caused by dysbiosis can result in a gradual decline of functional redundancy, either as a consequence of disease or its treatment. A recent study demonstrated that colorectal cancer is influenced by the co-occurrence of species, including *Vescimonas coprocola* and *Vescimonas fastidiosa*, although they did not significantly differ in abundance [61]. Metagenomic studies based on colorectal cancer datasets have reported an association between specific microbial species and this type of cancer [62-70]. For example, multiple studies have demonstrated the main role of particular species in the development of colorectal cancer [71], such as *Streptococcus gallolyticus* [72], *Bacteroides fragilis* [73,74] and *Fusobacterium nucleatum* [75-77]. Moreover, it has been proposed that *Bacteroides fragilis* [73,74] and *Fusobacterium nucleatum* [75-77] are key factors in the tumorigenesis process and then they may be replaced by "passenger" species that are favored by the cancer microenvironment [78].

The intake of DMB together with nutritional treatment and individualized dietary advice results in positive changes in the intestinal microbiome of cancer patients and patients with dysgeusia, which are correlated with taste perception in the DMB high dose group. By utilizing these strategies, patients with cancer are able to maintain their nutritional intake and enjoy their meals despite changes in taste perception and aftertaste [79]. It is, however, important for patients to discuss their dietary preferences and modifications with healthcare professionals in order to ensure that they receive adequate nutrition while undergoing cancer treatment [79]. The ability to manipulate gut microbiome composition to improve cancer therapy outcomes is a significant new area of research [80,81]. Intestinal microbiome composition is susceptible to changes due to diet and the environment, so educating patients on food consumption during cancer treatment and avoiding carcinogens may improve outcomes [80,81].

Cancer patients receiving a standard dose or a higher dose of DMB experienced different changes in their gut microbiota from those receiving a placebo. The difference could be attributed to the sweet taste experienced following the ingestion of orodispersible DMB tablets before each main meal, compared to the placebo group, which may lead to a better dietary intake.

4. Materials and Methods

4.1. Statement of ethical principles

This project was approved by University Hospital La Paz's (HULP Code 6164) Scientific Research and Ethics Committee in June 2022. According to the Declaration of Helsinki's Ethical Standards, this study adheres to recommendations for physicians conducting biomedical research on humans. The ICH Harmonized Tripartite Guidelines should be familiarized and followed by all researchers in order to maintain good clinical practices.

The research team informed the patients (verbally and in writing) of the study characteristics and the responsibilities of participation in the trial before they signed the

informed consent form. Patients were informed during the study that they could withdraw from the study at any time by notifying their doctor without giving a reason. The processing of personal information is subject to several legal requirements, including Spanish Organic Law 3/2018 of 5 December and the General Data Protection Regulation of the European Union (EU) 2016/679 of 27 April 2016.

4.2. *Participants and experimental design*

Detailed information of CLINMIR study is published elsewhere [43,45]. Briefly, the CLINMIR study is a pilot randomized, parallel, triple-blind, and placebo-controlled clinical trial. Using the number NCT05486260, the present protocol was registered at http://clinicaltrials.gov, accessed on 14 March 2024. An oncology service and clinical nutrition unit at HULP in Madrid recruited 31 malnourished cancer patients with taste disorders.

Three treatment arms were randomly assigned to malnourished patients with cancer and taste disorders who were receiving active treatment. A miraculin-based food supplement was administered to patients five minutes prior to each meal (breakfast, lunch, and dinner) during a three-month study. The tablets contained either DMB at one of its two dosages or a placebo [43,45].

Each intervention group consisted of ten patients who were randomly assigned to receive one of two DMB dosages or a placebo. In the first arm of the study, 150 mg of DMB equivalent to 2.8 mg of miraculin is combined with 150 mg of freeze-dried strawberries; in the second arm, 300 mg of DMB is utilized equivalent to 5.5 mg of miraculin; and in the third arm, 300 mg of freeze-dried strawberries are used as a placebo. Each of the three treatments was isocaloric (Table S1). The subjects received as many tablets as necessary during scheduled visits to the HULP in order to complete the three-month intervention period [43,45].

4.3. *Sequencing of biological samples*

To prepare for the analyses, sterile plastic containers were used to collect fecal samples at baseline and 3 months after intervention. Blood samples were collected by trained personnel at the HULP Extraction Unit in the morning (approximately at 8:00 am) during blood tests before chemotherapy to avoid unnecessary punctures and hospitalizations. The blood samples were collected in vacuum tubes, labeled, transported, and centrifuged at 1500 x g for 10 minutes. We prepared and labeled aliquots of blood samples according to a numerical code and stored them at -80 °C.

4.3.1. Extraction of DNA

QIAamp Fast DNA Stool Mini kit (ref. ID: 51604, Qiagen Inc., Hilden, Germany) was used to extract DNA from the stool samples. The purity and integrity of DNA were determined using spectrophotometry (NanoDrop, Thermo Fisher Scientific, Massachusetts, USA).

4.3.2. 16S rRNA gene sequencing and taxonomic assignment

A detailed description of 16S sequencing via Oxford Nanopore Technologies can be found elsewhere [44]. Briefly, the 16S rRNA gene was PCR-amplified using redesigned 16S primers (27F and 1492R) with 5' tags that facilitate ligase-free attachment. By vortexing 30 µl of AMPure XP beads (Beckman Coulter, ThermoScientific, Spain), and mixing by pipetting, PCR products from each sample were cleaned.

In order to achieve a concentration of 50-100 fmoles, all barcoded libraries were combined in the appropriate ratios. The final library was loaded into the SpotON Flow Cell Mk R9 Version (ref. FLO-MIN106D, Oxford Nanopore Technologies, Oxford, United Kingdom) using the Minion M1kc and M1kb sequencers (Oxford Nanopore Technologies, Oxford, United Kingdom).

After the raw data had been generated, searches were performed via Guppy version 6.5.7 (Oxford Nanopore Technologies, Oxford, United Kingdom), and sequences

were identified using Kraken2 (refseq Archaea, bacteria, viral, plasmid, human, UniVec_Core, protozoa, fungi & plant database) and further analyzed using QIIME2 [82]. Assigning taxonomy to ASVs was performed using the classify sklearn naïve Bayes taxonomy classifier (via q2-feature-classifier) [83] using SILVA 16S V3-V4 v132_99 [84] with a similarity threshold of 99%. The diversity of the samples was examined using the vegan library [85]. In this study, Shannon, Simpson and Chao1 indices were examined.

4.4. *Plasma cytokines*

Plasma tumor necrosis factor-alpha (TNF-α), and human proteolysis-inducing factor (PIF) were analyzed as previously described [86].

4.5. *Dietary pattern assessment*

For three days, including one holiday, daily food records were kept. Patients were advised to record household measurements (spoonfuls, cups, etc.) or household weights in the absence of weight records. A nutritionist reviewed all records in the presence of the patient to ensure that the information collected was accurate and complete. DIAL software (Alce Ingeniera, Madrid, Spain) was used to convert the energy and nutrients contained in foods, drinks, dietary supplements, and preparations. Finally, the results were compared with the recommended intakes for the Spanish population [43,45].

4.6. *Short-chain fatty acids determination by gas chromatography/mass spectrometry*

One hundred µl of plasma were individually placed in 1.5 ml tubes. Afterward, 10 µL of acidified water (15 % phosphoric acid v/v), and 10 µl of internal standards (sodium acetate ^{13}C2 at 300 µM, butyric-1,2-^{13}C2 at 60 µM and isobutyric acid d6, valeric acid d9, isovaleric acid d9 and propionic d6 acid at 30 µM) are added and vigorously mixed up. Next, a liquid-liquid extraction was performed with 150 µl of MTBE. The extraction was assisted by vortexing for 10 minutes. At this point, tubes were centrifuged at 15000 rpm for 10 minutes at 4 ºC. One hundred µl were transferred into a vial with an insert. The vials were centrifuged at 1000 rpm for 30s at 4 ºC and 1 µl was injected into gas chromatography/mass spectrometry. Briefly, short-chain fatty acids were separated on a DB-FFAP chromatographic column (30 m x 0.25 mm x 0.25 µm). The oven temperature was programmed as follows: (i) initial temperature 40 ºC, (ii) linearly increased at 12 ºC/min until 130 ºC (0 min), (iii) then linearly raised at 30 ºC/min to 200 ºC (0 min) and (iv) in the final step the temperature was ramped at 100 ºC/min to 250 ºC (4.5 min). The column flow was set at 1.5 ml/min with Helium as carrier gas. The injector was set at 250 ºC and the extract was injected in a split-less mode. Using electronic impact (70 eV) for ionization, the mass analyzer was operated for multi reaction monitoring.

4.7. *Statistical analysis*

To examine the effects of time, treatment, and their interaction (time x treatment), a linear mixed model was used to examine the differences between placebo, 150 mg of DMB, and 300 mg DMB. Using the R program, a linear mixed model was developed using the lme4 package [87]. A median test revealed significant differences across time points within groups.

We also examined the relationships between intestinal microbiome variables, inflammatory parameters, dietary variables, short-chain fatty acids, and electrical taste perception outcomes via Pearson's correlations; for that purpose we used the R Studio's corrplot function [88] correcting multiple testing using the FDR procedure [89]. Only significant and corrected associations are shown in the graphs. The red and blue lines in the graphs indicate correlation values, with negative correlations highlighted in red (−1) and positive correlations highlighted in blue (+1).

Rivera-Pinto analysis can identify microbial signatures, i.e., groups of microbes capable of predicting particular phenotypes of interest. This microbial signature may be used to diagnose, prognosticate, or predict therapeutic response on the basis of the unique microbiota of an individual. Identifying microbial signatures requires modeling the

response variable and selecting the taxa that are the most accurate at classification or prediction. To select a sparse model that adequately explains the response variable, we evaluated specific signatures at the phylum and genus levels using the Rivera-Pinto method and the Selbal algorithm. Based on data collected from two groups of taxa, microbial signatures were calculated using geometric means. These groups are those with relative abundances or balances that are related to the response variable of interest [46].

5. Conclusions

This pilot randomized, parallel, triple-blind, and placebo-controlled clinical trial identified a putative innovative therapeutic option for the management of taste disorders in patients with cancer. This novel strategy was designed with the intent of reducing the adverse effects associated with chemotherapeutic, radiotherapeutic, and immunotherapeutic interventions, which may include alterations in taste, changes in body composition and nutritional status, and alterations in the quality of life [45]. Here, we observed differences between the genera *Phocaeicola* and *Escherichia* depending on the treatment. Only the *Solibaculum* genus increased in relative abundance in the DMB group after 3 months. With respect to species, *Bacteroides* sp. PHL 2737 had a lower relative abundance in both DMB groups, and *Vescimonas coprocola* exhibited a greater abundance in both treatments after 3 months. Moreover, a standard dose of DMB was positively associated with TNF-α levels and *Lachnoclostridium* and *Mediterraneibacter* abundances, whereas a high dose of DMB was negatively associated with TNF-α levels and the relative abundance of *Phocaeicola*. After high- dose DMB administration, a positive correlation was found between PUFAs, *Lachnoclostridium*, and *Roseburia*. Additionally *Phocaeicola* was positively correlated with acetic acid levels. Accordingly, DMB intake and nutritional treatment positively modify the intestinal microbiome in patients with cancer and dysgeusia, which might lead to a greater immunological response and better dietary intake.

Supplementary Materials: The following supporting information can be downloaded at: www.mdpi.com/xxx/s1, Table S1: Nutritional composition of the food supplement enriched in miraculin (DMB) and placebo.

Author Contributions: Conceptualization, B.L.-P., A.G. and S.P.-M.; methodology, B.L.-P. and J.F.-B.; software, J.D.-P.; validation, F.J.R.-O, A.I.A.-M. and M.B.-H.; formal data analysis, J.D.-P., F.J.R.-O, and M.B.-H.; investigation, B.L.-P and L.A.-C.; resources, S.P.-M.; data curation, L.A.-C; writing-original draft preparation, J.D.-P., F.J.R.-O, M.B.-H. and A.G.; writing-review and editing, J.D.-P., F.J.R.-O, M.B.-H. and A.G.; supervision, S.P.-M and A.G.; project administration, B.L.-P; funding acquisition, S.P.-M. All authors have read and agreed to the published version of the manuscript.

Funding: This study is funded by Medicinal Gardens S.L. through the Center for Industrial Technological Development (CDTI), "Cervera" Transfer R&D Projects. Ref. IDI-20210622. (Science and Education Ministry, Spain).

Institutional Review Board Statement: The study was conducted under the Declaration of Helsinki, and approved by the Ethics Committee of La Paz University Hospital (protocol code 6164, 23 June 2022).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: A reasonable request should be made to the corresponding author for access to the datasets used and/or analyzed in the current study.

Acknowledgments: J.P.-D. is part of the "UGR Plan Propio de Investigación 2016" and the "Excellence actions: Unit of Excellence in Exercise and Health (UCEES), University of Granada". F.J.R.-O. is supported by a grant from the Spanish Government's "Agencia Estatal de Investigación-Juan de la Cierva-Incorporación" program (IJC2020-042739-I). We thank (Lucía Tadeo, Helena Torrell, Adría Cereto and Núria Canela) from the Genomics facility of the Centre for Omic Sciences (COS) Joint Unit of the Universitat Rovira i Virgili-Eurecat, for their contributions to the sequencing analysis.

Conflicts of Interest: The authors declare that they have no commercial or financial relationships that could be construed as potential conflicts of interest.

References

1. Brown, J.S.; Amend, S.R.; Austin, R.H.; Gatenby, R.A.; Hammarlund, E.U.; Pienta, K.J. Updating the Definition of Cancer. *Mol Cancer Res* **2023**, *21*, 1142-1147, doi:10.1158/1541-7786.MCR-23-0411.
2. World Health Organization (WHO). Cancer. Availabe online: https://www.who.int/health-topics/cancer#tab=tab_1 (accessed on 2024-06-14).
3. FitzGerald, T.J.; Bishop-Jodoin, M.; Laurie, F.; Sacher, A.; Aghababian, R.V.; Dickson, E. Treatment Toxicity: Radiation. In *Oncologic Emergency Medicine: Principles and Practice*, Todd, K.H., Thomas, J.C.R., Eds. Springer International Publishing: Cham, 2016; 10.1007/978-3-319-26387-8_34pp. 407-419.
4. Arends, J.; Baracos, V.; Bertz, H.; Bozzetti, F.; Calder, P.C.; Deutz, N.E.P.; Erickson, N.; Laviano, A.; Lisanti, M.P.; Lobo, D.N., et al. ESPEN expert group recommendations for action against cancer-related malnutrition. *Clin Nutr* **2017**, *36*, 1187-1196, doi:10.1016/j.clnu.2017.06.017.
5. Amezaga, J.; Alfaro, B.; Rios, Y.; Larraioz, A.; Ugartemendia, G.; Urruticoechea, A.; Tueros, I. Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment. *Support Care Cancer* **2018**, *26*, 4077-4086, doi:10.1007/s00520-018-4277-z.
6. Denda, Y.; Niikura, N.; Satoh-Kuriwada, S.; Yokoyama, K.; Terao, M.; Morioka, T.; Tsuda, B.; Okamura, T.; Ota, Y.; Tokuda, Y., et al. Taste alterations in patients with breast cancer following chemotherapy: a cohort study. *Breast Cancer* **2020**, *27*, 954-962, doi:10.1007/s12282-020-01089-w.
7. Fark, T.; Hummel, C.; Hahner, A.; Nin, T.; Hummel, T. Characteristics of taste disorders. *Eur Arch Otorhinolaryngol* **2013**, *270*, 1855-1860, doi:10.1007/s00405-012-2310-2.
8. Campagna, S.; Gonella, S.; Sperlinga, R.; Giuliano, P.L.; Marchese, R.; Pedersini, R.; Berchialla, P.; Dimonte, V. Prevalence, Severity, and Self-Reported Characteristics of Taste Alterations in Patients Receiving Chemotherapy. *Oncol Nurs Forum* **2018**, *45*, 342-353, doi:10.1188/18.ONF.342-353.
9. Spotten, L.E.; Corish, C.A.; Lorton, C.M.; Ui Dhuibhir, P.M.; O'Donoghue, N.C.; O'Connor, B.; Walsh, T.D. Subjective and objective taste and smell changes in cancer. *Ann Oncol* **2017**, *28*, 969-984, doi:10.1093/annonc/mdx018.
10. Bleumer, T.; Abel, J.; Bohmerle, W.; Schroder, S.; Yap, S.A.; Schaeper, N.D.E.; Hummel, T.; Stintzing, S.; Stephan, L.U.; Pelzer, U. Smell and Taste Alterations in Patients Receiving Curative or Palliative Chemotherapy-The CONKO 021-ChemTox Trial. *Cancers (Basel)* **2024**, *16*, doi:10.3390/cancers16142495.
11. Hovan, A.J.; Williams, P.M.; Stevenson-Moore, P.; Wahlin, Y.B.; Ohrn, K.E.; Elting, L.S.; Spijkervet, F.K.; Brennan, M.T.; Dysgeusia Section, O.C.S.G., Multinational Association of Supportive Care in Cancer /International Society of Oral Oncology. A systematic review of dysgeusia induced by cancer therapies. *Supportive care in cancer* **2010**, *18*, 1081-1087.
12. Erkurt, E.; Erkisi, M.; Tunali, C. Supportive treatment in weight-losing cancer patients due to the additive adverse effects of radiation treatment and/or chemotherapy. *Journal of Experimental & Clinical Cancer Research: CR* **2000**, *19*, 431-439.
13. Whitcroft, K.L.; Altundag, A.; Balungwe, P.; Boscolo-Rizzo, P.; Douglas, R.; Enecilla, M.L.B.; Fjaeldstad, A.W.; Fornazieri, M.A.; Frasnelli, J.; Gane, S., et al. Position paper on olfactory dysfunction: 2023. *Rhinology* **2023**, *61*, 1-108, doi:10.4193/Rhin22.483.
14. Togni, L.; Mascitti, M.; Vignini, A.; Alia, S.; Sartini, D.; Barlattani, A.; Emanuelli, M.; Santarelli, A. Treatment-related dysgeusia in oral and oropharyngeal cancer: A comprehensive review. *Nutrients* **2021**, *13*, 3325.
15. Wilken, M.K.; Satiroff, B.A. Pilot study of" miracle fruit" to improve food palatability for patients receiving chemotherapy. *Clinical Journal of Oncology Nursing* **2012**, *16*.
16. Solemdal, K.; Sandvik, L.; Willumsen, T.; Mowe, M.; Hummel, T. The impact of oral health on taste ability in acutely hospitalized elderly. *PLoS One* **2012**, *7*, e36557, doi:10.1371/journal.pone.0036557.
17. Merkonidis, C.; Grosse, F.; Ninh, T.; Hummel, C.; Haehner, A.; Hummel, T. Characteristics of chemosensory disorders--results from a survey. *Eur Arch Otorhinolaryngol* **2015**, *272*, 1403-1416, doi:10.1007/s00405-014-3210-4.

18. Dominiak, H.S.; Hasselsteen, S.D.; Nielsen, S.W.; Andersen, J.R.; Herrstedt, J. Prevention of taste alterations in patients with cancer receiving Paclitaxel-or Oxaliplatin-based chemotherapy—A pilot trial of cannabidiol. *Nutrients* **2023**, *15*, 3014. 658 659
19. Epstein, J.B.; de Andrade e Silva, S.M.; Epstein, G.L.; Leal, J.H.S.; Barasch, A.; Smutzer, G. Taste disorders following cancer treatment: report of a case series. *Supportive Care in Cancer* **2019**, *27*, 4587-4595. 660 661
20. Heckmann, S.M.; Hujoel, P.; Habiger, S.; Friess, W.; Wichmann, M.; Heckmann, J.G.; Hummel, T. Zinc gluconate in the treatment of dysgeusia--a randomized clinical trial. *J Dent Res* **2005**, *84*, 35-38, doi:10.1177/154405910508400105. 662 663
21. Riquelme, E.; Zhang, Y.; Zhang, L.; Montiel, M.; Zoltan, M.; Dong, W.; Quesada, P.; Sahin, I.; Chandra, V.; San Lucas, A. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. *Cell* **2019**, *178*, 795-806. e712. 664 665
22. Pushalkar, S.; Hundeyin, M.; Daley, D.; Zambirinis, C.P.; Kurz, E.; Mishra, A.; Mohan, N.; Aykut, B.; Usyk, M.; Torres, L.E. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. *Cancer discovery* **2018**, *8*, 403-416. 666 667 668
23. de Vos, W.M.; de Vos, E.A. Role of the intestinal microbiome in health and disease: from correlation to causation. *Nutrition reviews* **2012**, *70*, S45-S56. 669 670
24. Lozupone, C.A.; Stombaugh, J.I.; Gordon, J.I.; Jansson, J.K.; Knight, R. Diversity, stability and resilience of the human gut microbiota. *Nature* **2012**, *489*, 220-230, doi:10.1038/nature11550. 671 672
25. Grenham, S.; Clarke, G.; Cryan, J.F.; Dinan, T.G. Brain-gut-microbe communication in health and disease. *Front Physiol* **2011**, *2*, 94, doi:10.3389/fphys.2011.00094. 673 674
26. Enaud, R.; Vandenborght, L.E.; Coron, N.; Bazin, T.; Prevel, R.; Schaeverbeke, T.; Berger, P.; Fayon, M.; Lamireau, T.; Delhaes, L. The Mycobiome: A Neglected Component in the Microbiota-Gut-Brain Axis. *Microorganisms* **2018**, *6*, doi:10.3390/microorganisms6010022. 675 676 677
27. Goralczyk-Binkowska, A.; Szmajda-Krygier, D.; Kozlowska, E. The Microbiota-Gut-Brain Axis in Psychiatric Disorders. *Int J Mol Sci* **2022**, *23*, doi:10.3390/ijms231911245. 678 679
28. Carding, S.; Verbeke, K.; Vipond, D.T.; Corfe, B.M.; Owen, L.J. Dysbiosis of the gut microbiota in disease. *Microbial ecology in health and disease* **2015**, *26*, 26191. 680 681
29. Virtue, A.T.; McCright, S.J.; Wright, J.M.; Jimenez, M.T.; Mowel, W.K.; Kotzin, J.J.; Joannas, L.; Basavappa, M.G.; Spencer, S.P.; Clark, M.L. The gut microbiota regulates white adipose tissue inflammation and obesity via a family of microRNAs. *Science translational medicine* **2019**, *11*, eaav1892. 682 683 684
30. Koh, A.; Molinaro, A.; Ståhlman, M.; Khan, M.T.; Schmidt, C.; Mannerås-Holm, L.; Wu, H.; Carreras, A.; Jeong, H.; Olofsson, L.E. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. *Cell* **2018**, *175*, 947-961. e917. 685 686
31. Rekdal, V.; Bess, E.; Bisanz, J.; Turnbaugh, P.; Balskus, E. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science 364: eaau6323. 2019. 687 688
32. Jin, C.; Lagoudas, G.K.; Zhao, C.; Bullman, S.; Bhutkar, A.; Hu, B.; Ameh, S.; Sandel, D.; Liang, X.S.; Mazzilli, S. Commensal microbiota promote lung cancer development via γδ T cells. *Cell* **2019**, *176*, 998-1013. e1016. 689 690
33. El Tekle, G.; Garrett, W.S. Bacteria in cancer initiation, promotion and progression. *Nat Rev Cancer* **2023**, *23*, 600-618, doi:10.1038/s41568-023-00594-2. 691 692
34. Plummer, M.; de Martel, C.; Vignat, J.; Ferlay, J.; Bray, F.; Franceschi, S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. *The Lancet Global Health* **2016**, *4*, e609-e616. 693 694
35. de Martel, C.; Georges, D.; Bray, F.; Ferlay, J.; Clifford, G.M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. *The Lancet global health* **2020**, *8*, e180-e190. 695 696
36. Cullin, N.; Azevedo Antunes, C.; Straussman, R.; Stein-Thoeringer, C.K.; Elinav, E. Microbiome and cancer. *Cancer Cell* **2021**, *39*, 1317-1341, doi:10.1016/j.ccell.2021.08.006. 697 698
37. Hou, K.; Wu, Z.X.; Chen, X.Y.; Wang, J.Q.; Zhang, D.; Xiao, C.; Zhu, D.; Koya, J.B.; Wei, L.; Li, J., et al. Microbiota in health and diseases. *Signal Transduct Target Ther* **2022**, *7*, 135, doi:10.1038/s41392-022-00974-4. 699 700

38. Hekmatshoar, Y.; Saadat, Y.R.; Khatibi, S.M.H.; Ozkan, T.; Vahed, F.Z.; Nariman-Saleh-Fam, Z.; Gargari, B.P.; Sunguroglu, A.; Vahed, S.Z. The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental? *Life sciences* **2019**, *233*, 116680.
39. Gomez de Cedron, M.; Wagner, S.; Reguero, M.; Menendez-Rey, A.; de Molina, A.R. Miracle Berry as a Potential Supplement in the Control of Metabolic Risk Factors in Cancer. *Antioxidants (Basel)* **2020**, *9*, doi:10.3390/antiox9121282.
40. Soares, H.; Cusnir, M.; Schwartz, M.; Pizzolato, J.; Lutzky, J.; Campbell, R.; Beaumont, J.; Eton, D.; Stonick, S.; Lilenbaum, R. Treatment of taste alterations in chemotherapy patients using the "miracle fruit": Preliminary analysis of a pilot study. *Journal of Clinical Oncology* **2010**, *28*, e19523-e19523.
41. Osabor, V.; Etiuma, R.; Ntinya, M. Chemical profile of leaves and roots of miracle fruit (Synsepalum dulcificum). *American Chemical Science Journal* **2016**, *12*, 1-8.
42. He, Z.; Tan, J.S.; Abbasiliasi, S.; Lai, O.M.; Tam, Y.J.; Ariff, A.B. Phytochemicals, nutritionals and antioxidant properties of miracle fruit Synsepalum dulcificum. *Industrial Crops and Products* **2016**, *86*, 87-94.
43. López-Plaza, B.; Gil, Á.; Menéndez-Rey, A.; Bensadon-Naeder, L.; Hummel, T.; Feliú-Batlle, J.; Palma-Milla, S. Effect of Regular Consumption of a Miraculin-Based Food Supplement on Taste Perception and Nutritional Status in Malnourished Cancer Patients: A Triple-Blind, Randomized, Placebo-Controlled Clinical Trial-CLINMIR Pilot Protocol. *Nutrients* **2023**, *15*, doi:10.3390/nu15214639.
44. Plaza-Diaz, J.; Ruiz-Ojeda, F.J.; López-Plaza, B.; Brandimonte-Hernández, M.; Álvarez-Mercado, A.I.; Arcos-Castellanos, L.; Feliú-Batlle, J.; Hummel, T.; Palma-Milla, S.; Gil, A. Effect of a novel food rich in miraculin on the oral microbiome of malnourished oncologic patients with dysgeusia. *medRxiv* **2024**, 10.1101/2024.07.12.24310343, 2024.2007.2012.24310343, doi:10.1101/2024.07.12.24310343.
45. López-Plaza, B.; Álvarez-Mercado, A.I.; Arcos-Castellanos, L.; Plaza-Diaz, J.; Ruiz-Ojeda, F.J.; Brandimonte-Hernández, M.; Feliú-Batlle, J.; Hummel, T.; Gil, Á.; Palma-Milla, S. Efficacy and Safety of Habitual Consumption of a Food Supplement Containing Miraculin in Malnourished Cancer Patients: The CLINMIR Pilot Study. *Nutrients* **2024**, *16*, 1905, doi:10.3390/nu16121905.
46. Rivera-Pinto, J.; Egozcue, J.J.; Pawlowsky-Glahn, V.; Paredes, R.; Noguera-Julian, M.; Calle, M.L. Balances: a New Perspective for Microbiome Analysis. *mSystems* **2018**, *3*, doi:10.1128/mSystems.00053-18.
47. Hes, C.; Desilets, A.; Tonneau, M.; El Ouarzadi, O.; De Figueiredo Sousa, M.; Bahig, H.; Filion, E.; Nguyen-Tan, P.F.; Christopoulos, A.; Benlaifaoui, M., et al. Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma. *Oral Oncol* **2024**, *148*, 106623, doi:10.1016/j.oraloncology.2023.106623.
48. Ma, C.; Han, M.; Heinrich, B.; Fu, Q.; Zhang, Q.; Sandhu, M.; Agdashian, D.; Terabe, M.; Berzofsky, J.A.; Fako, V. Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells. *Science* **2018**, *360*, eaan5931.
49. Luck, R.; Deppenmeier, U. Genetic tools for the redirection of the central carbon flow towards the production of lactate in the human gut bacterium Phocaeicola (Bacteroides) vulgatus. *Appl Microbiol Biotechnol* **2022**, *106*, 1211-1225, doi:10.1007/s00253-022-11777-6.
50. Nabavi, S.F.; Bilotto, S.; Russo, G.L.; Orhan, I.E.; Habtemariam, S.; Daglia, M.; Devi, K.P.; Loizzo, M.R.; Tundis, R.; Nabavi, S.M. Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials. *Cancer and Metastasis Reviews* **2015**, *34*, 359-380.
51. Watson, H.; Mitra, S.; Croden, F.C.; Taylor, M.; Wood, H.M.; Perry, S.L.; Spencer, J.A.; Quirke, P.; Toogood, G.J.; Lawton, C.L., et al. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. *Gut* **2018**, *67*, 1974-1983, doi:10.1136/gutjnl-2017-314968.
52. Olsson, L.M.; Boulund, F.; Nilsson, S.; Khan, M.T.; Gummesson, A.; Fagerberg, L.; Engstrand, L.; Perkins, R.; Uhlen, M.; Bergström, G. Dynamics of the normal gut microbiota: a longitudinal one-year population study in Sweden. *Cell host & microbe* **2022**, *30*, 726-739. e723.

53. Tudela, H.; Claus, S.P.; Saleh, M. Next generation microbiome research: identification of keystone species in the metabolic regulation of host-gut microbiota interplay. *Frontiers in cell and developmental biology* **2021**, *9*, 719072.
54. Chaput, N.; Lepage, P.; Coutzac, C.; Soularue, E.; Le Roux, K.; Monot, C.; Boselli, L.; Routier, E.; Cassard, L.; Collins, M. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. *Annals of Oncology* **2017**, *28*, 1368-1379.
55. Gopalakrishnan, V.; Spencer, C.N.; Nezi, L.; Reuben, A.; Andrews, M.C.; Karpinets, T.V.; Prieto, P.; Vicente, D.; Hoffman, K.; Wei, S.C. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. *Science* **2018**, *359*, 97-103.
56. Coutzac, C.; Jouniaux, J.-M.; Paci, A.; Schmidt, J.; Mallardo, D.; Seck, A.; Asvatourian, V.; Cassard, L.; Saulnier, P.; Lacroix, L. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. *Nature communications* **2020**, *11*, 2168.
57. Limeta, A.; Ji, B.; Levin, M.; Gatto, F.; Nielsen, J. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma. *JCI insight* **2020**, *5*.
58. Spencer, C.N.; McQuade, J.L.; Gopalakrishnan, V.; McCulloch, J.A.; Vetizou, M.; Cogdill, A.P.; Khan, M.A.W.; Zhang, X.; White, M.G.; Peterson, C.B. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. *Science* **2021**, *374*, 1632-1640.
59. Lili, L.; Ye, J. Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study. *Medicine* **2020**, *99*, e21788.
60. Newsome, R.C.; Gharaibeh, R.Z.; Pierce, C.M.; da Silva, W.V.; Paul, S.; Hogue, S.R.; Yu, Q.; Antonia, S.; Conejo-Garcia, J.R.; Robinson, L.A. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. *Genome Medicine* **2022**, *14*, 35.
61. Riveros Escalona, M.A.; Poloni, J.F.; Krause, M.J.; Dorn, M. Meta-analyses of host metagenomes from colorectal cancer patients reveal strong relationship between colorectal cancer-associated species. *Mol Omics* **2023**, *19*, 429-444, doi:10.1039/d3mo00021d.
62. Zuo, W.; Michail, S.; Sun, F. Metagenomic analyses of multiple gut datasets revealed the association of phage signatures in colorectal cancer. *Frontiers in cellular and infection microbiology* **2022**, *12*, 918010.
63. Arthur, J.C.; Perez-Chanona, E.; Mühlbauer, M.; Tomkovich, S.; Uronis, J.M.; Fan, T.-J.; Campbell, B.J.; Abujamel, T.; Dogan, B.; Rogers, A.B. Intestinal inflammation targets cancer-inducing activity of the microbiota. *science* **2012**, *338*, 120-123.
64. Heshiki, Y.; Vazquez-Uribe, R.; Li, J.; Ni, Y.; Quainoo, S.; Imamovic, L.; Li, J.; Sørensen, M.; Chow, B.K.; Weiss, G.J. Predictable modulation of cancer treatment outcomes by the gut microbiota. *Microbiome* **2020**, *8*, 1-14.
65. Thomas, A.M.; Manghi, P.; Asnicar, F.; Pasolli, E.; Armanini, F.; Zolfo, M.; Beghini, F.; Manara, S.; Karcher, N.; Pozzi, C. Author Correction: Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. *Nature medicine* **2019**, *25*, 1948-1948.
66. Ulger Toprak, N.; Yagci, A.; Gulluoglu, B.; Akin, M.; Demirkalem, P.; Celenk, T.; Soyletir, G. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. *Clinical microbiology and infection* **2006**, *12*, 782-786.
67. Wirbel, J.; Pyl, P.T.; Kartal, E.; Zych, K.; Kashani, A.; Milanese, A.; Fleck, J.S.; Voigt, A.Y.; Palleja, A.; Ponnudurai, R. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. *Nature medicine* **2019**, *25*, 679-689.
68. Zeller, G.; Tap, J.; Voigt, A.Y.; Sunagawa, S.; Kultima, J.R.; Costea, P.I.; Amiot, A.; Böhm, J.; Brunetti, F.; Habermann, N. Potential of fecal microbiota for early‐stage detection of colorectal cancer. *Molecular systems biology* **2014**, *10*, 766.
69. Briscoe, L.; Balliu, B.; Sankararaman, S.; Halperin, E.; Garud, N.R. Evaluating supervised and unsupervised background noise correction in human gut microbiome data. *PLOS Computational Biology* **2022**, *18*, e1009838.

70. Yachida, S.; Mizutani, S.; Shiroma, H.; Shiba, S.; Nakajima, T.; Sakamoto, T.; Watanabe, H.; Masuda, K.; Nishimoto, Y.; Kubo, M. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. *Nature medicine* **2019**, *25*, 968-976.
71. Sankar, S.A.; Lagier, J.-C.; Pontarotti, P.; Raoult, D.; Fournier, P.-E. The human gut microbiome, a taxonomic conundrum. *Systematic and applied microbiology* **2015**, *38*, 276-286.
72. Abdulamir, A.S.; Hafidh, R.R.; Mahdi, L.K.; Al-jeboori, T.; Abubaker, F. Investigation into the controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma. *BMC cancer* **2009**, *9*, 1-12.
73. Boleij, A.; Hechenbleikner, E.M.; Goodwin, A.C.; Badani, R.; Stein, E.M.; Lazarev, M.G.; Ellis, B.; Carroll, K.C.; Albesiano, E.; Wick, E.C. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. *Clinical Infectious Diseases* **2015**, *60*, 208-215.
74. Sears, C.L.; Geis, A.L.; Housseau, F. Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. *The Journal of clinical investigation* **2014**, *124*, 4166-4172.
75. McCoy, A.N.; Araújo-Pérez, F.; Azcarate-Peril, A.; Yeh, J.J.; Sandler, R.S.; Keku, T.O. Fusobacterium is associated with colorectal adenomas. *PloS one* **2013**, *8*, e53653.
76. Kostic, A.D.; Chun, E.; Robertson, L.; Glickman, J.N.; Gallini, C.A.; Michaud, M.; Clancy, T.E.; Chung, D.C.; Lochhead, P.; Hold, G.L. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. *Cell host & microbe* **2013**, *14*, 207-215.
77. Nosho, K.; Sukawa, Y.; Adachi, Y.; Ito, M.; Mitsuhashi, K.; Kurihara, H.; Kanno, S.; Yamamoto, I.; Ishigami, K.; Igarashi, H. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. *World journal of gastroenterology* **2016**, *22*, 557.
78. Loftus, M.; Hassouneh, S.A.-D.; Yooseph, S. Bacterial community structure alterations within the colorectal cancer gut microbiome. *BMC microbiology* **2021**, *21*, 1-18.
79. Garutti, M.; Noto, C.; Pasto, B.; Cucciniello, L.; Alajmo, M.; Casirati, A.; Pedrazzoli, P.; Caccialanza, R.; Puglisi, F. Nutritional Management of Oncological Symptoms: A Comprehensive Review. *Nutrients* **2023**, *15*, doi:10.3390/nu15245068.
80. Rinninella, E.; Raoul, P.; Cintoni, M.; Franceschi, F.; Miggiano, G.A.D.; Gasbarrini, A.; Mele, M.C. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. *Microorganisms* **2019**, *7*, doi:10.3390/microorganisms7010014.
81. Dunnack, H.J.; Judge, M.P.; Cong, X.; Salner, A.; Duffy, V.B.; Xu, W. An Integrative Review of the Role of the Oral and Gut Microbiome in Oral Health Symptomatology During Cancer Therapy. *Oncol Nurs Forum* **2021**, *48*, 317-331, doi:10.1188/21.ONF.317-331.
82. Bolyen, E.; Rideout, J.R.; Dillon, M.R.; Bokulich, N.A.; Abnet, C.C.; Al-Ghalith, G.A.; Alexander, H.; Alm, E.J.; Arumugam, M.; Asnicar, F., et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol* **2019**, *37*, 852-857, doi:10.1038/s41587-019-0209-9.
83. Bokulich, N.A.; Kaehler, B.D.; Rideout, J.R.; Dillon, M.; Bolyen, E.; Knight, R.; Huttley, G.A.; Gregory Caporaso, J. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin. *Microbiome* **2018**, *6*, 90, doi:10.1186/s40168-018-0470-z.
84. Quast, C.; Pruesse, E.; Yilmaz, P.; Gerken, J.; Schweer, T.; Yarza, P.; Peplies, J.; Glockner, F.O. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids Res* **2013**, *41*, D590-596, doi:10.1093/nar/gks1219.
85. Dixon, P. VEGAN, a package of R functions for community ecology. *Journal of vegetation science* **2003**, *14*, 927-930.
86. Alvarez-Mercado, A.I.; Lopez-Plaza, B.; Plaza-Diaz, J.; Arcos-Castellano, L.; Ruiz-Ojeda, F.J.; Brandimonte-Hernandez, M.; Feliu-Batlle, J.; Hummel, T.; Palma-Milla, S.; Gil, A. The Regular Consumption of a Food Supplement Containing Miraculin Can Contribute to Reducing Biomarkers of Inflammation and Cachexia in Malnourished Patients with Cancer and Taste

Disorders: The CLINMIR Pilot Study. *medRxiv* **2024**, 10.1101/2024.06.23.24309349, 2024.2006.2023.24309349, doi:10.1101/2024.06.23.24309349.

87. Wang, T.; Graves, B.; Rosseel, Y.; Merkle, E.C. Computation and application of generalized linear mixed model derivatives using lme4. *Psychometrika* **2022**, *87*, 1173-1193, doi:10.1007/s11336-022-09840-2.

88. Wei, T.S., V; Levy, M; Xie, Y; Jin Y; Zemla, J; Freidank, M; Cai, J; Protivinsky, T. Package 'corrplot'. *https://github.com/taiyun/corrplot* **2022**.

89. Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B (Methodological)* **1995**, *57*, 289-300, doi:https://doi.org/10.1111/j.2517-6161.1995.tb02031.x.